Independent evidence guideReviewed 12 Aug 2026

Fish oil,
minus the fishy claims.

A practical guide to who may benefit, which products have real outcome data, when to take them—and how to tell if anything changed.

See the evidence map Decode your label

Not personal medical advice. High triglycerides, pregnancy and high doses deserve a clinician or pharmacist—not a supplement aisle guess.

START WITH YOUR REASON

01 High triglycerides →02 General heart health →03 Pregnancy →04 Mood / joints / eyes →

01 / EVIDENCE MAP

Where the signal is—and isn’t.

“Lowers a biomarker” and “prevents illness” are different claims. The strongest evidence is tied to a specific goal, product and dose.

01
Strong

Lowering high triglycerides

Prescription omega-3 at 4 g/day reliably lowers triglycerides. This is treatment, not a wellness dose, and should be monitored with blood tests.

Measure: fasting triglycerides
02
Selected patients

Reducing cardiovascular events

Prescription EPA-only icosapent ethyl reduced events in statin-treated people at high cardiovascular risk with raised triglycerides. Mixed EPA+DHA products have not reproduced that result.

Prescription only
03
Useful in context

Pregnancy

DHA/EPA can reduce preterm birth risk, with the clearest case in people with low omega-3 status or low fish intake. Dose and timing belong in antenatal care.

Ask your antenatal clinician
04
Not established

A first heart attack in healthy adults

Routine low-dose fish oil has not consistently prevented major cardiovascular events in otherwise healthy adults. Eating fish within a healthy diet has better support.

Food first
05
Mixed / uncertain

Mood, joints and dry eye

Trials are inconsistent. There may be small, formulation-specific benefits for some people, but fish oil is not a replacement for proven treatment.

Time-box any trial
06
Doesn’t work

Preventing dementia or ‘detoxing’ inflammation

There is no convincing clinical evidence that capsules prevent cognitive decline in healthy people, and ‘general inflammation’ is not a useful treatment target.

Skip the claim

The prescription result cannot be reverse-engineered from a supermarket bottle.

REDUCE-IT tested 4 g/day of purified EPA-only icosapent ethyl in statin-treated, high-risk patients. STRENGTH tested a different high-dose EPA+DHA formulation and was neutral. Formulation and patient selection are part of the treatment.

Read REDUCE-IT ↗

02 / THE BOTTLE

Choose the active ingredient, not the front label.

A “1,000 mg fish oil” capsule may provide only 300 mg of EPA + DHA. Turn the bottle around.

EPA180 mg
DHA120 mg
WHAT COUNTS300 mg

Ignore “total fish oil”.
Add EPA + DHA per capsule, then multiply by the capsules you actually take.

Icosapent ethyl

EPA only · prescription

Works for a narrow, high-risk group

The product with cardiovascular outcome evidence. It is not equivalent to an EPA-heavy supplement.

Prescription EPA + DHA

Usually 4 g/day

Works for triglyceride lowering

Can lower triglycerides, but has not shown the same cardiovascular event benefit as EPA-only icosapent ethyl.

Concentrated fish oil

Check EPA + DHA

Delivers omega-3; not a heart drug

Reasonable when oily fish is not practical. Choose by actual EPA+DHA per serve, not by the large ‘fish oil’ number.

Algae oil

DHA, sometimes EPA

A sound fish-free source

Useful for vegans, fish allergy or pregnancy when the label provides the intended DHA/EPA amount.

Krill oil

Often lower-dose

No proven clinical advantage

It supplies EPA and DHA, but better absorption claims have not translated into better health outcomes. Often pricier per gram.

Cod liver oil

Omega-3 + vitamins A/D

Poor choice for dose-chasing

EPA/DHA dosing can bring unwanted vitamin A. Extra caution in pregnancy; use a purpose-made prenatal product instead.

Flax / chia ALA

Plant omega-3

Healthy food; not EPA/DHA-equivalent

Conversion of ALA into EPA—and especially DHA—is limited. Do not count ALA milligram-for-milligram as marine omega-3.

Gummies and ‘3-6-9’ blends

Usually low payload

Mostly marketing

Often expensive per gram of EPA+DHA, while omega-6 and omega-9 are already abundant in ordinary diets.

QUALITY CHECK

Four things worth paying for

  1. 1

    Clear EPA and DHA amounts per capsule—not only “omega-3 blend”.

  2. 2

    An Australian AUST L or AUST R number and a traceable batch. Listing is a quality/safety baseline, not proof the health claim works.

  3. 3

    A realistic use-by date and storage directions. Heat, light and air degrade oils; keep the lid closed and follow the label.

  4. 4

    The lowest capsule burden that delivers the intended EPA+DHA. Adherence beats premium-sounding chemistry.

03 / TIMING

Take it with dinner.
Or lunch. Just not on hope.

There is no proven magic hour. Meal context and consistency matter more than morning versus night.

01

Pair it with a proper meal

A meal containing some fat improves absorption, especially for ethyl ester forms, and can reduce stomach upset. Breakfast works if it is more than black coffee.

02

Split bigger doses

If your prescriber or label permits, divide a large daily dose across two meals. This often makes reflux and fishy aftertaste easier to tolerate.

03

Use the same cue each day

Keep it beside something you already use at a meal. A theoretically superior oil that sits in the cupboard has zero bioavailability.

04

Follow the medicine label

Prescription products have product-specific instructions. Do not change the dose or substitute an over-the-counter product without your prescriber.

04 / LABEL CALCULATOR

How much EPA + DHA are you actually taking?

Enter the amounts listed per capsule. This checks the arithmetic, not whether the dose is right for you.

YOUR DAILY EPA + DHA

600 mg

A common supplement range—but not proven to act like prescription therapy.

The 3,000 mg scale here is a caution marker, not a recommended target.

05 / DID IT WORK?

Decide what success means before the first capsule.

Fish oil rarely creates a useful “feeling”. Match the measurement to the reason you started.

TG

For high triglycerides

Record a fasting lipid panel before treatment, then repeat at the interval your clinician sets—often around 6–12 weeks. The target is a meaningful triglyceride change, not a fishy aftertaste.

BASELINERECHECKDECIDE
↯

For symptoms

Choose one trackable measure—such as morning stiffness minutes or a validated mood score. Keep other treatment stable. Stop a self-directed trial if there is no meaningful change after 8–12 weeks.

2×

For a dietary gap

Success may simply be consistently reaching two serves of fish a week, or an agreed DHA/EPA intake when fish is not suitable. Most people do not need a blood omega-3 test.

Ω

About the omega-3 index

It reflects longer-term red-cell EPA+DHA, but there is no universally accepted treatment target for routine healthy adults. A number going up does not prove a health outcome improved.

06 / SAFETY

More is not automatically better.

High doses can be appropriate. That is exactly why they should have a reason, a review and a stop rule.

Talk to a clinician first if you have atrial fibrillation, palpitations, a bleeding disorder, planned surgery, pregnancy, or take an anticoagulant.

Higher-dose omega-3 has been linked to a dose-related rise in atrial fibrillation in cardiovascular trials. Clinically significant bleeding is uncommon, but medicine interactions and monitoring still matter.

COMMON

Reflux, nausea, loose stools

Take with a meal, split the dose if allowed, or stop if the burden exceeds the benefit.

CHECK

Anticoagulants and antiplatelets

Do not assume “natural” means interaction-free. Tell your pharmacist and prescriber your actual EPA+DHA dose.

AVOID

Megadosing from multiple products

Add up fish oil, prenatal, fortified foods and prescription omega-3. A regulatory safety ceiling is not a target.

ALLERGY

Fish or shellfish allergy

Ask about algae-derived DHA/EPA and check capsule ingredients. Do not trial marine oil through a known serious allergy.

SOURCE NOTES

Evidence, not endorsements.

Prioritised: current guidelines, government reviews, systematic reviews and large randomised trials. No brand paid for inclusion.

01
2026 ACC/AHA dyslipidemia guidelineNonprescription fish oil is not recommended for lipid lowering or ASCVD benefit.
↗02
NIH Omega-3 Fact SheetForms, evidence, pregnancy, safety and interactions. Updated Aug 2025.
↗03
AHA hypertriglyceridemia advisoryPrescription omega-3 at 4 g/day effectively lowers triglycerides.
↗04
STRENGTH randomised trialHigh-dose EPA+DHA did not reduce major cardiovascular events.
↗05
2025 atrial fibrillation meta-analysis34 randomised trials; risk varied with dose and baseline cardiovascular risk.
↗06
Australian TGA medicines guidanceWhat AUST L, AUST L(A) and AUST R do—and do not—mean.
↗

Evidence search current to 12 August 2026 · This page is educational and cannot account for your diagnoses, medicines or pathology results.